Antibody Design

We are a young biotech startup and our aim is to develop the next generation of influenza diagnostics. Influenza virus is a big problem. It affects over 10% of the world’s population every year with 650,000 deaths annually. The economical impact is massive: 87 billions US dollars per year, and these numbers continue to grow. The market is dominated by rapid tests with an average sensitivity of only 50%, not enough to be deployed effectively. We are developing a diagnostic solution with higher probability of virus detection and increased diagnostic performance.